GLP-1RA have shown to control HbA1C levels in patients with T2DM alongside alleviating the frequently existing comorbids, HTN and dyslipidaemia in combination with SGLT2 inhibitors (115). The gene discussed is SLC5A2; the disease is inherited lipid metabolism disorder.